Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05692518
Other study ID # GTM-005
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date December 19, 2022
Est. completion date February 15, 2025

Study information

Verified date January 2024
Source GT Metabolic Solutions, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this clinical research study is to evaluate the feasibility of the GT Metabolic Solutions DI Bio-fragmentable Magnetic Anastomosis System (MAGNET System, DI Bio-fragmentable) for creation of a side-by-side anastomosis duodeno-ileostomy in obese adults.


Description:

The purpose of this clinical research study is to evaluate the feasibility of the GT Metabolic Solutions DI Bio-fragmentable Magnetic Anastomosis System (MAGNET System, DI Bio-fragmentable) for creation of a side-to-side anastomosis duodeno-ileostomy in obese adults. This partial diversion of intestinal contents from duodenum to the ileum is intended to facilitate weight management/loss in obese adults with type 2 diabetes mellitus (T2DM) and improve metabolic outcomes in obese adults with type 2 diabetes mellitus (T2DM). Side-by-side anastomoses are currently created by sutures, staples, and anastomotic compression devices. A predicate procedure is the single-anastomosis duodeno-ileostomy (SADI) procedure.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 9
Est. completion date February 15, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. 18-65 years of age, inclusive, at the time of informed consent 2. BMI 30-35 kg/m2 3. Type 2 diabetes mellitus (T2DM), defined as HbA1c > 6.5%, without previous sleeve gastrectomy, and without plan to perform a concurrent sleeve gastrectomy. 4. Agrees to refrain from any type of additional bariatric or reconstructive surgery that would affect body weight for the duration of the study 5. If a child-bearing female, subject must commit to not becoming pregnant and agree to use contraception for the duration of the study 6. Willing and able to comply with protocol requirements Exclusion Criteria: 1. Type 1 diabetes 2. Use of injectable insulin 3. Uncontrolled T2DM 4. Previous sleeve gastrectomy procedure or plan to perform a sleeve gastrectomy with the duodeno-ileal anastomosis procedure 5. Uncontrolled hypertension, dyslipidemia or sleep apnea 6. Prior intestinal, colonic or duodenal surgery, other than bariatric 7. Prior surgery, trauma, prostheses, disease or genetic expression which prevent or contra-indicate the procedure, including scarring and abnormal anatomy. 8. Refractory gastro-esophageal reflux disease (GERD) 9. Barrett's disease 10. Helicobacter pylori positive and/or active ulcer disease 11. Large hiatal hernia 12. Inflammatory bowel or colonic diverticulitis disease 13. Any anomaly precluding orogastric access by gastroscope and catheters, and manipulation techniques. 14. Implantable pacemaker or defibrillator 15. Psychiatric disorder, except well-controlled depression with medication for > 6 mo 16. History of substance abuse 17. Woman who is either pregnant or breast feeding 18. Woman of childbearing potential who does not agree to use an effective method of contraception. 19. Any comorbidity or current status of subject's physiological fitness that in the surgeon's or anesthesiologist's opinion represents safety concerns that make the subject medically unfit for the procedure. 20. Any anomaly preventing/contraindicating laparoscopic access and general laparoscopic procedures 21. Had surgical or interventional procedure within 30 days prior to procedure 22. Any scheduled surgical or interventional procedure planned within 30 days post-procedure 23. Any stroke/transient ischemic attack (TIA) within 6 months prior to consent 24. Requires chronic anticoagulation therapy (except aspirin) 25. Active infections requiring antibiotic therapy, unless resolved before undergoing the study procedure 26. Unable to comply with the follow-up schedule and assessments 27. Recent tobacco or nicotine product cessation within < 3 months prior to informed consent 28. Known allergies to the device components or contrast media 29. Limited life expectancy due to terminal disease 30. Currently participating in another clinical research study with an investigational drug or medical device 31. A positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 or COVID-19) test prior to the study procedure in accordance with local COVID-19 protocol 32. Any condition that, in the investigator's opinion, may preclude completion of follow-up assessments through Day 360 (e.g., a medical condition that may increase the risk associated with study participation or may interfere with interpretation of study results, inability to adhere to the visit schedule, or poor compliance with treatment regimen)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
MAGNET System, DI Bio-fragmentable
Anastomoses achieved by magnetic compression.

Locations

Country Name City State
Georgia Innova Medical Center Tbilisi

Sponsors (1)

Lead Sponsor Collaborator
GT Metabolic Solutions, Inc.

Country where clinical trial is conducted

Georgia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Creation of a patent anastomosis Confirmed radiologically or fluoroscopically 30 Days
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2